Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPP4C | P60510 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 2/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.85 |
| ▸ | MAP1B | P46821 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fostriecin SCHEMBL62527 | 0.99 | PPP4C (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL10738899 | 0.99 | PPP4C (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL469219 | 0.99 | PPP4C (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL10738892 | 0.99 | PPP4C (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL10030539 | 0.99 | PPP4C (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL31052709 | 0.92 | MAPT (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL21408783 | 0.92 | MAPT (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL29370092 | 0.92 | MAPT (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| SCHEMBL444441 | 0.92 | PPP4C (0.86) | PPP4CMAPTTDP1MAP1BMEN1 | |
| SCHEMBL442237 | 0.92 | PPP4C (0.86) | PPP4CMAPTTDP1MAP1BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9050 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4524131-A1 | SMALL MOLECULES FOR TREATING CANCER, INHABITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | AlonBio Ltd. (IL) | 2025-03-19 | — | — | EP | claimed |
| US-12202803-B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | ALONBIO LTD. (IL) | 2025-01-21 | — | — | US | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| US-12109219-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | claimed |
| EP-4401780-A1 | AMORPHOUS PHOTOSENSITIZING PARTICLES, METHODS FOR THE PREPARATION THEREOF, AND METHODS FOR THE USE THEREOF | University of Maryland, College Park (US) | 2024-07-24 | — | — | EP | claimed |
| WO-2024026505-A2 | DISRUPTION OF TELOCYTE ACTIVITY | PATEL AMIT (US) | 2024-02-01 | — | — | WO | claimed |
| US-20240002347-A1 | SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | ALONBIO LTD. (IL) | 2024-01-04 | — | — | US | claimed |
| WO-2023044436-A1 | AMORPHOUS PHOTOSENSITIZING PARTICLES, METHODS FOR THE PREPARATION THEREOF, AND METHODS FOR THE USE THEREOF | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2023-03-23 | — | — | WO | claimed |
| WO-2008039254-A9 | RNA NANOPARTICLES AND NANOTUBES | US GOV HEALTH & HUMAN SERV (US) | 2008-08-07 | — | — | WO | claimed |
| US-20080176853-A1 | e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders | ABRAXIS BIOSCIENCE, INC. (US) | 2008-07-24 | — | — | US | claimed |
| WO-2008076883-A2 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, INC. (US) | 2008-06-26 | — | — | WO | claimed |
| WO-2008062466-A2 | CINNAMIC ACID, VANILLIC ACID AND BENZOFURAN DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION AND CANCER | RELIANCE LIFE SCIENCES PVT. LTD. (IN) | 2008-05-29 | — | — | WO | claimed |
| WO-2008039254-A2 | RNA NANOPARTICLES AND NANOTUBES | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-04-03 | — | — | WO | claimed |
| WO-2007059116-A2 | GELDANAMYCIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ABRAXIS BIOSCIENCE, INC. (US) | 2007-05-24 | — | — | WO | claimed |
| US-20060079472-A1 | Methods for treating angiogenesis | ANGIOSYN, INC. | 2006-04-13 | — | — | US | claimed |
| US-20040092583-A1 | Treatment for inhibiting neoplastic lesions | SHANAHAN-PRENDERGAST ELIZABETH (IE) | 2004-05-13 | — | — | US | claimed |
| EP-1351678-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | Shanahan-Prendergast, Elizabeth (IE) | 2003-10-15 | — | — | EP | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |